Eli Lilly’s $214M Ad Spend Yet Captures 60% of U.S. Obesity Drug Market
Eli Lilly spent $214 million on U.S. ads for Zepbound and Mounjaro in January–September 2025 versus Novo Nordisk's $487 million. Despite lower marketing, Lilly holds about 60% of the U.S. obesity drug market, and data show Zepbound users lost 47% more weight than Wegovy.
1. CEO Highlights Medicare Coverage as Key Catalyst
Eli Lilly CEO Dave Ricks told CNBC that the company expects Medicare to begin covering obesity drugs immediately following the launch of its experimental oral GLP-1 weight loss pill, orforglipron. Ricks said this coverage could “change the game” by reducing out-of-pocket costs for patients who currently pay cash for competitor treatments. He confirmed Lilly’s plan for a full commercial launch in the second quarter, timed to coincide with new federal reimbursement policies secured under pricing agreements struck in November with the previous administration.
2. Advertising Spend and Market Share Leadership
In 2025, Eli Lilly allocated approximately $131 million to promote its obesity therapy Zepbound and $83 million for its diabetes treatment Mounjaro, for a total outlay of $214 million through September. Despite being outspent two to one by Novo Nordisk’s combined $487 million on Wegovy and Ozempic, Lilly captured roughly 60% of U.S. obesity drug prescriptions last year, according to IQVIA data cited by Reuters. Ricks attributed this market share advantage to targeted direct-to-provider initiatives and clinical messaging differentiating Zepbound’s efficacy profile.
3. Demonstrated Clinical Superiority of Zepbound
Late-stage trial results released in 2024 showed patients treated with Zepbound experienced 47% greater mean weight loss compared with those taking Wegovy in a head-to-head study of over 1,200 participants. Lilly executives have spotlighted this data in investor presentations, emphasizing both the depth of Zepbound’s adipose tissue reduction and improvements in cardiometabolic markers observed over a 52-week period. These findings underpin the company’s confidence in sustaining growth against strong incumbent brands.
4. Investor Sentiment Fueled by Media Commentary
‘Mad Money’ host Jim Cramer recently spotlighted Eli Lilly as a standout name in biotech, citing the company’s robust pipeline and the upcoming orforglipron launch as triggers for a renewed analyst review. Several brokerage firms have reiterated ‘overweight’ ratings on Lilly shares, noting that successful Medicare integration and continued prescription share gains in obesity care could drive mid-single-digit revenue growth in 2026, with upside from further trial readouts and potential label expansions.